Evidence map›Paper›PMID 32430662›Full record

ReviewStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2020

The brave new world of endometrial cancer : Future implications for adjuvant treatment decisions.

S Marnitz, T Waltar, C Köhler, A Mustea, B Schömig-Markiefka

Abstract readReview
PubMed Publisher
In one paragraph

Review in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. [The PORTEC-3 trial for high-risk endometrial cancer: impact of molecular classification on prognosis and benefit from adjuvant therapy].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

S MarnitzMedical Faculty, Department of Radiation Oncology, CyberKnife and Radiotherapy, University Cologne, Kerpener Str. 62, 50937, Cologne, Germany. simone.marnitz-schulze@uk-koeln.de.ORCID http://orcid.org/0000-0001-6739-7768
T WaltarMedical Faculty, Department of Radiation Oncology, CyberKnife and Radiotherapy, University Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
C KöhlerDepartment for Specialized Laparoscopic Surgery, Asklepios Clinic Hamburg-Altona, Hamburg, Germany.
A MusteaMedical Faculty, Department of Gynecology, University Clinic Bonn, Bonn, Germany.
B Schömig-MarkiefkaMedical Faculty, Institute of Pathology, University Cologne, Cologne, Germany.
University of Cologne · DEAsklepios Klinik Altona · DEUniversity Hospital Bonn · DEUniversity Hospital Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFor many decades, endometrial cancer (EC) has been considered as a homogenous tumor entity with good prognosis. The currently valid risk stratification considers clinical and pathological factors. Treatment recommendations differ considerably from country to country. MATERIALS AND

methodsThe Cancer Genome Atlas (TCGA) Research Network has shown that ECs should be reclassified into four novel molecular prognostic groups, with the potential of changing adjuvant management of EC patients: ultra-mutated, hyper-mutated, copy-number low, and copy-number high. Clinical examples are shown, and the available literature has been highlighted. The European Society of Gynaecological Oncology (ESGO) guideline for endometrial cancer takes the new classification system into consideration for adjuvant treatment decisions and will be published this year.

resultsIn the near future, we expect new treatment recommendations that may differ considerably from the clinicopathologically driven recommendations on the basis of our deeper insight and better understanding of molecular markers in endometrial cancer. The PORTEC 4a study is the only recruiting study which randomizes patients to adjuvant or no adjuvant treatment on the basis of the aforementioned new classification system.

conclusionThe aim of the new classification is a more personalized adjuvant radio(chemo)therapy decision and better oncologic outcomes or avoidance of overtreatment.

Indexed as

Radiotherapy, AdjuvantBiomarkers, TumorCarcinomaCarcinoma, EndometrioidClinical Decision-MakingEndometrial NeoplasmsEstrogensFemaleForecastingGene DosageGenes, NeoplasmHumansMicrosatellite InstabilityMutationNeoplasms, Hormone-DependentPrecision MedicineBiomarkers, TumorEstrogensProgesteroneAdjuvant radiationBrachytherapyRisk classificationSurvivalUterus carcinoma

Identifiers

PMID32430662
OpenAlexW3028294551

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.